Basit öğe kaydını göster

dc.contributor.authorAkoglu, Gulsen
dc.contributor.authorLi, Qiaoli
dc.contributor.authorGokoz, Ozay
dc.contributor.authorGazyagci, Ali Serhan
dc.contributor.authorUitto, Jouni
dc.date.accessioned2019-12-12T06:40:10Z
dc.date.available2019-12-12T06:40:10Z
dc.date.issued2014
dc.identifier.issn0011-9059
dc.identifier.urihttps://doi.org/10.1111/ijd.12008
dc.identifier.urihttp://hdl.handle.net/11655/16500
dc.description.abstractBackgroundPseudoxanthoma elasticum (PXE) is a heritable ectopic mineralization disorder affecting cutaneous, ocular, and cardiovascular systems, caused by mutations in the ABCC6 gene. PXE presents with a marked clinical and genetic heterogeneity. Furthermore, heterozygous carriers may present with limited histopathological features. This study was conducted to investigate a patient with PXE and her family members clinically, histopathologically, and genetically. MethodsClinical and histopathological examinations and mutation analyses of ABCC6 gene were performed. ResultsLesional skin biopsy of the patient with PXE demonstrated clumping and fragmentation of elastic fibers, and calcification in the dermis. Non-lesional axillary skin samples of the husband, daughter, and older son were histopathologically normal. The skin from a similar region of a younger son revealed elastic fibers with some fragmentation and clumping but no mineralization. The patient with PXE was homozygous for the R1141X mutation in the ABCC6 gene. The husband had wild-type alleles, while all children were heterozygous carriers. Daily treatment of antioxidant therapy with tocopherol acetate and ascorbic acid was prescribed to the patient with PXE. After oneyear, both clinical and histopathological regression of the lesions was observed; however, lesions began to progress during the additional 6-month period of treatment. ConclusionThe mutation analyses of ABCC6 gene are important to determine the genotype of both patients with PXE and putative heterozygous carriers, as histopathological features of carriers may differ even in the same family. The role of antioxidant therapy for PXE is unclear, and there is a need for controlled clinical trials.
dc.language.isoen
dc.publisherWiley
dc.relation.isversionof10.1111/ijd.12008
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectDermatology
dc.titleClinical And Histopathological Characteristics Of A Family With R1141X Mutation Of Pseudoxanthoma Elasticum - Presymptomatic Testing And Lack Of Carrier Phenotypes
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalInternational Journal Of Dermatology
dc.contributor.departmentTıbbi Patoloji
dc.identifier.volume53
dc.identifier.issue6
dc.identifier.startpage692
dc.identifier.endpage698
dc.description.indexWoS


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster